IngredientsThe term diethylphenethylamine is an umbrella designation used in the dietary supplement and forensic-toxicology literature to describe a small family of synthetic phenethylamine derivatives in which two ethyl groups replace two hydrogen atoms on the core phenethylamine scaffold. In practice, three structural isomers carry this name and have all been detected in commercial products:
N,α-DEPEA is a close chemical analog of methamphetamine, which has been sold as a designer drug. The structural relationship is straightforward: whereas methamphetamine bears a methyl group at the α-carbon of phenethylamine, N,α-DEPEA bears an ethyl group at the α-carbon and an additional ethyl group on the nitrogen, making it a di-ethyl homolog of amphetamine.
The parent compound, phenethylamine (PEA) is an organic compound and natural monoamine alkaloid. In mammals, phenethylamine is produced from the amino acid L-phenylalanine by the enzyme aromatic L-amino acid decarboxylase via enzymatic decarboxylation. Diethylphenethylamine isomers are synthetic derivatives of this parent molecule and are not products of normal mammalian or plant biosynthesis.
Substituted phenethylamines are the group of phenethylamine derivatives that contain phenethylamine as a backbone. This chemical class includes all substituted amphetamines and contains many drugs that act as stimulants, psychedelics, anorectics, and antidepressants, among others.
A pivotal aspect of the diethylphenethylamine controversy is the fraudulent or misleading attribution of a natural botanical source. The pre-workout supplement Craze (Driven Sports, Inc.) listed an extract of Dendrobium orchids on its label and implied that diethylphenethylamine isomers were natural constituents of this plant. Independent scientific analysis refuted this claim.
Phenylethylamine derivatives are not naturally present in species belonging to the genus Dendrobium. "The phenylethylamine we identified in Craze, N,α-DEPEA, is not listed on the labeling and it has not been previously identified as a derivative of dendrobium orchids," noted lead investigator Dr. Pieter Cohen of Harvard Medical School.
Similarly, Dendrobium nobile, an orchid, was rumoured to be a source of DEPEA â the compound that became infamous in the Craze dietary supplement. The FDA issued a warning letter in 2014.
The only diethylated phenethylamine with a verified natural botanical source is the dimethyl analog N,N-dimethylphenethylamine (N,N-DMPEA), which, while structurally related, is a distinct compound. N,N-DMPEA is a substituted phenethylamine that is used as a flavoring agent; it is an alkaloid that was first isolated from the orchid Pinalia jarensis. This compound is sold in supplements under the label "Eria jarensis extract," and is not the same molecule as N,N-DEPEA; however, both are marketed under the informal name "diethylphenethylamine" in commercial contexts, contributing to significant consumer confusion.
Neither N,α-DEPEA nor N,N-DEPEA has any documented history of traditional or pre-modern use. Both are entirely synthetic compounds whose existence in the scientific literature dates only to the late twentieth and early twenty-first centuries. No ethnobotanical tradition, historical pharmacopoeia, or folk medicine system has employed these specific molecules, because they are not found naturally in botanicals used by any traditional healing culture.
N,α-DEPEA is a relatively understudied substance with few scientific references published regarding its properties. The substance was first described in a scientific paper in 1991 by Noggle et al., but was allegedly patented in 1988 by Knoll Pharmaceuticals.
NADEP (N,α-DEPEA) was patented in 1988 by Knoll Pharmaceuticals with claims of psychoactive effects, including cognitive enhancement and pain tolerance. It was originally patented by Knoll Pharma as one of several analogs for pharmaceutical applications. In animal models these analogs showed properties of cognitive enhancement and increased pain tolerance. Nevertheless, this class of compounds was never developed into a medicine.
The parent compound phenethylamine itself has a longer indirect history in foods. Phenethylamine is a chemical that is naturally found in the brain and in a wide range of vegetables, fruits, nuts, and spices; it is also sometimes used as a food flavoring. However, none of the diethylated derivatives discussed in this article derive from this nutritional or traditional context.
Diethylphenethylamine isomers entered the dietary supplement market primarily from 2012 onward, following regulatory action against the stimulant DMAA (1,3-dimethylamylamine). DEPEA was marketed as a replacement to DMAA in pre-workout products, representing a deliberate commercial strategy rather than any claim of traditional therapeutic heritage.
Dietary supplements often contain additives not listed on the label, including α-ethyl homologs of amphetamine such as N,α-diethylphenethylamine (DEPEA). The compound has been identified in concentrated powdered pre-workout formulations, typically sold in flavored, multi-ingredient blends. Products in which DEPEA isomers have been analytically confirmed include the pre-workout supplements "Craze" and "Detonate."
DEPEA has been detected as an ingredient in various sport supplements like "Craze" or "Detonate."
The product label of Craze listed "Dendrobium extract" as a source of diethylphenethylamine. The Craze product label did not state that the product contains N,α-DEPEA; however, N,N-DEPEA, a structural isomer of N,α-DEPEA, was stated as a constituent of the added Dendrobium extract. This created a situation where the label acknowledged one isomer while masking the presence of the more pharmacologically concerning N,α isomer.
In a 2025 analysis of sports supplements marketed as containing Eria jarensis orchid extract â a product purportedly supplying N,N-DMPEA (the dimethyl homolog) â widespread inaccurate labeling and undeclared or variable ingredient quantities were revealed. A study examining 12 such products found that four contained no detectable N,N-DMPEA, while the remaining eight had doses ranging from 0.1 mg to 41 mg per serving, far exceeding or falling short of implied amounts based on extract concentrations; additionally, levels of co-ingredients like caffeine, hordenine, and synephrine were inaccurately reported, raising concerns over dosing reliability and potential overdose risks.
DEPEA is a mixed norepinephrineâdopamine releasing agent (NDRA) and norepinephrineâdopamine reuptake inhibitor (NDRI). It is a full releaser of norepinephrine but a weak partial releaser of dopamine with a maximal efficacy of about 40% in rat brain synaptosomes.
A detailed in vitro and in vivo pharmacological characterisation was performed by Schindler et al. (2021) at the National Institute on Drug Abuse (NIDA) Intramural Research Program. The neurochemical and cardiovascular effects of α-ethylphenethylamine (AEPEA), N-methyl-α-ethylphenethylamine (MEPEA), and DEPEA were examined as compared with amphetamine. All drugs were tested in vitro using uptake inhibition and release assays for monoamine transporters. Amphetamine acted as a potent and efficacious releasing agent at dopamine transporters (DAT) and norepinephrine transporters (NET) in vitro.
AEPEA and MEPEA were also releasers at catecholamine transporters, with greater potency at NET than DAT. DEPEA displayed fully efficacious release at NET but weak partial release at DAT (i.e., 40% of maximal effect).
A 2022 study in the European Neuropsychopharmacology journal further characterised the transporter profile: while both amphetamine and N,α-DEPEA potently inhibited norepinephrine uptake, N,α-DEPEA was less dopaminergic than amphetamine (DAT/SERT ratio >10). Moreover, as a transporter blocker, N,α-DEPEA also bound with the highest affinity to NET and DAT.
DEPEA is a low-potency agonist of the rat trace amine-associated receptor 1 (TAAR1) (ECâ â = 3,500 nM) but was inactive as an agonist of the mouse and human TAAR1 at least up to the maximal assessed concentrations (ECâ â > 4,400 nM and 30,000 nM, respectively).
In a broader study of phenethylamine analogs found in pre-workout supplements, although the health effects of these analogues are not well understood, they are hypothesised to be agonists of adrenergic (ADR) and trace amine-associated receptors (TAARs). Researchers aimed to pharmacologically characterise these compounds by investigating their activating properties of ADRs and TAAR1 in vitro. Multiple PEAs activated ADRs (ECâ â = 34 nMâ690 ”M; Emax = 8â105%). Almost all PEAs activated TAAR1 (ECâ â = 1.8â92 ”M; Emax = 40â104%).
A critical secondary mechanism relevant to safety is interaction with monoamine oxidase (MAO), the primary metabolic enzyme for monoamines. Phenethylamines can interact with the metabolic enzyme monoamine oxidase (MAO), which can cause neurochemical dysfunction or changes in drug potency.
In an in vitro study examining N,α-DEPEA and its metabolite AEPEA specifically: in vitro inhibition of human recombinant MAO by AEPEA and N,α-DEPEA was evaluated by measuring fluorescence of 4-hydroxyquinoline produced from MAO substrate kynuramine. AEPEA competitively inhibited human recombinant MAO A (Ki = 14.0 ”M), which was 17-fold stronger compared to MAO B (Ki = 234 ”M). Furthermore, N,α-DEPEA was a weak inhibitor of both MAO A (Ki = 251 ”M) and MAO B (Ki = 159 ”M).
The MAO inhibition exerted by the metabolite AEPEA is notably more potent than that of the parent DEPEA and has implications for drug-drug interactions (see Section 8).
All three PEA analogs (BMPEA, AEPEA, and DEPEA) act as substrate-type releasers at the rat norepinephrine transporter (NET), which leads to increases in blood pressure and heart rate. This NET-mediated mechanism is the principal driver of the cardiovascular effects documented in preclinical studies.
Evidence type: Preclinical (animal) only. No human clinical studies exist.
N,α-DEPEA is described in the patent literature but, to the best of the available evidence, has never been studied in humans. N,α-DEPEA has been described in only a small number of peer-reviewed publications.
In the landmark 2021 NIDA study published in the Journal of Pharmacology and Experimental Therapeutics, AEPEA (1â10 mg/kg, s.c.) produced significant increases in blood pressure but not heart rate or activity, whereas DEPEA and MEPEA (1â10 mg/kg, s.c.) increased blood pressure, heart rate, and activity. In general, the phenethylamine analogs were approximately 10-fold less potent than amphetamine.
Like amphetamine, MEPEA and DEPEA increased locomotor activity, suggesting these agents could have central effects, including abuse potential in humans.
N,α-DEPEA has not been studied in humans, but experts such as Pieter Cohen of Harvard Medical School expect it to be less potent than methamphetamine, but greater than ephedrine.
Strength of evidence: All CNS stimulant effects are derived from preclinical animal models only. There are no randomised controlled trials, observational studies, or any other form of human clinical evidence for any purported benefit of DEPEA as a dietary supplement ingredient.
Evidence type: Preclinical (animal) studies; limited human case reports relating to adverse events.
The cardiovascular pharmacology of N,α-DEPEA has been investigated in freely moving rats instrumented with biotelemetry transmitters. Similar to amphetamine, AEPEA and MEPEA function as efficacious neurotransmitter releasers at DAT and NET, but with greater potency at NET relative to DAT. By contrast, DEPEA displays efficacious release at NET but low-efficacy partial release at DAT. Despite these minor differences from amphetamine in neurochemical mechanism, all three α-ethyl PEA analogs increased blood pressure similar to amphetamine, although at reduced potency. MEPEA and DEPEA also increased heart rate. As a result, these compounds could produce toxic effects if taken in large enough amounts.
All three PEA analogs act as substrate-type releasers at the rat norepinephrine transporter (NET), which leads to increases in blood pressure and heart rate. The PEA compounds are about 10-fold less potent than amphetamine at stimulating cardiovascular parameters.
The results show that α-ethylphenethylamine analogs are biologically active. Although less potent than amphetamine, they produce cardiovascular effects that could pose risks to humans.
Strength of evidence: The cardiovascular risk data are derived entirely from preclinical rat studies (Schindler et al., 2021, NIDA IRP). No controlled human cardiovascular studies exist. No efficacy data support cardiovascular benefit in humans.
Evidence type: Preclinical (animal) studies only.
A 2022 study published in Psychopharmacology by Schindler, Baumann, and colleagues at NIDA specifically examined whether DEPEA and related PEA analogs could sustain drug self-administration behaviour â a validated preclinical model of abuse liability. The reinforcing effects of AEPEA (1 mg/kg/injection), DEPEA (1 mg/kg/injection), and BMPEA (3 mg/kg/injection) were compared to amphetamine (0.1 mg/kg/injection) using a fixed-ratio 1 self-administration paradigm in male rats. Male rats were trained in self-administration chambers containing 2 nose-poke holes. A nose-poke response in the active hole delivered drug or saline, whereas a response in the inactive hole had no programmed consequence.
Amphetamine showed a typical inverted U-shaped dose-effect function, peaking at 0.1 mg/kg/injection. AEPEA and DEPEA also showed inverted dose-effect functions, with each peaking at 0.3 mg/kg/injection. BMPEA did not show an inverted U-shaped dose-effect function, but active responding slowly increased up to a dose of 6 mg/kg/injection.
Taken together, the findings indicate that dietary supplements containing PEA analogs may have significant abuse liability when used recreationally.
Given that MEPEA and DEPEA increased locomotor activity, these substances may also have significant abuse potential.
Strength of evidence: Preclinical rat models only. The self-administration data, while a validated surrogate for abuse potential, cannot be directly extrapolated to human behaviour. It is difficult to directly extrapolate the self-administration findings in rats to the potential abuse liability of PEA analogs in humans taking supplements.
Evidence type: Patent claims only; no peer-reviewed studies in any species.
NADEP (N,α-DEPEA) was patented in 1988 by Knoll Pharmaceuticals with claims of psychoactive effects, such as cognitive enhancement and pain tolerance. These claims originate from the original patent filing. This class of compounds was never developed into a medicine. No peer-reviewed pre-clinical or clinical studies have been published establishing cognitive enhancement or analgesic efficacy for DEPEA isomers.
Evidence type: None. No human or animal studies demonstrate benefit.
Researchers noted no empirical evidence supporting N,N-DMPEA's enhancement of athletic performance, attributing its inclusion in supplements to unsubstantiated hype as a "natural stimulant" despite structural similarity to synthetic amphetamine derivatives. The same absence of evidence applies to N,α-DEPEA and N,N-DEPEA in the context of sports performance.
The primary pharmacological actions of N,α-DEPEA are central: phenethylamine and its derivatives are central nervous system stimulants related to many psychoactive compounds such as the amphetamines and catecholamines. DEPEA specifically acts on dopaminergic and noradrenergic circuits via transporter substrate activity and reuptake inhibition.
Psychomotor stimulants like amphetamine and cocaine are known to have cardiovascular consequences such as increases in heart rate (HR) and blood pressure (BP). The cardiovascular effects of stimulants are due, at least in part, to their ability to elevate catecholamine levels, which mediate changes in HR and BP via the autonomic nervous system. DEPEA's full efficacy at NET, producing norepinephrine release from sympathetic nerve terminals, places it squarely within this framework.
In vitro nephrotoxicity has been studied for other members of the phenethylamine supplement class. Research at the FDA's National Center for Toxicological Research documented nephrotoxic effects when phenethylamine is combined with N,N-dimethylphenethylamine in renal cell models (Applied In Vitro Toxicology, 2016). While this work concerns the dimethyl, not diethyl, analog, it indicates that phenethylamine-class compounds at supplement-relevant concentrations can adversely affect renal physiology in vitro.
Research by Liu and Santillo (FDA, 2016) examined cytochrome P450 enzyme inhibition by amine stimulants found in dietary supplements, including compounds of the phenethylamine class (Drug Testing and Analysis, 2016). Inhibition of CYP2D6 and CYP3A4 â two of the most important enzymes in human drug metabolism â was documented. This creates a theoretical basis for clinically significant pharmacokinetic drug interactions.
No therapeutic dosing regimen has been established for any diethylphenethylamine isomer. The quantities described in the literature are derived entirely from analytical measurements of amounts present in adulterated commercial supplements.
For the preclinical self-administration studies, doses used in rats were 0.1 mg/kg/injection for amphetamine (comparator), and 1 mg/kg/injection for AEPEA and 1 mg/kg/injection for DEPEA.
N,α-DEPEA has never been studied in humans. N,α-DEPEA is a methamphetamine analog; however, its stimulant, addictive, and other adverse effects in humans are entirely unknown. This represents the foundational safety concern: supplement consumers have been unknowingly exposed to an untested synthetic amphetamine analog.
The α-ethylphenethylamine analogs are biologically active. While less potent than amphetamine, they produce cardiovascular effects that could pose risks to humans. The increases in blood pressure and heart rate observed in rat telemetry studies are physiologically plausible mechanisms for adverse cardiovascular events in humans, particularly during exercise when sympathetic tone is already elevated.
These compounds could produce toxic effects if taken in large enough amounts.
Given that MEPEA and DEPEA increased locomotor activity, these substances may also have significant abuse potential. The self-administration data from NIDA researchers corroborate this concern, with DEPEA and AEPEA both sustaining inverted-U-shaped dose-response self-administration curves typical of classical stimulants of abuse.
The metabolite of N,α-DEPEA, α-ethylphenethylamine (AEPEA), is a significant in vitro inhibitor of MAO-A (Ki = 14.0 ”M), as noted above. Phenethylamines can interact with the metabolic enzyme monoamine oxidase (MAO), which can cause neurochemical dysfunction or changes in drug potency. Concurrent use of MAO inhibitors (such as certain antidepressants) with phenethylamine-class stimulants carries a theoretical risk of serotonergic or hypertensive crises, a class-level concern applicable to this compound family.
These compounds are often not listed on the ingredient labels of dietary supplements and thus could pose a risk to humans using these products. Nutritional supplements often contain ingredients that are not listed on the product labels, including analogs of phenethylamine that display structural similarity to amphetamine.
Several athletes were disqualified from competition after testing positive for the methamphetamine analog N,α-DEPEA. Athletes claimed they had unknowingly consumed the banned stimulant in workout supplements.
The FDA acted to remove N,α-DEPEA-containing supplements from the market. The FDA issued a warning letter in 2014 regarding DEPEA-containing products.
N,α-DEPEA was detected in urine samples of professional competitors and was therefore prohibited by the World Anti-Doping Agency (WADA). A systematic review published in Frontiers in Sports and Active Living (2026) confirmed that synthetic derivatives of amphetamines, explicitly including N,α-DEPEA, are among the most commonly detected stimulant adulterants in dietary supplements used in sport.
Synthetic phenethylamine (PEA) analogs, such as ÎČ-methylphenethylamine (BMPEA) and N,α-diethylphenethylamine (DEPEA), are often found in dietary supplements, despite regulations prohibiting their sale.
The presence of multiple isomers in the same product complicates both toxicological assessment and regulatory enforcement. The Craze product label stated N,N-DEPEA as a constituent of Dendrobium extract, while from preliminary analysis a peak similar to N,α-DEPEA was detected; the compound was theoretically suggested to be N,ÎČ-DEPEA, another structural isomer with less structural similarity to methamphetamine. These close structural relationships make regulatory and forensic differentiation technically demanding.
The totality of scientific evidence concerning diethylphenethylamine isomers as dietary supplement ingredients is as follows:
Health conditions that Diethyl phenethylamine may help support.
Body systems that Diethyl phenethylamine may help support.
Go back